Cabozantinib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Cabozantinib

Examples of brand names: Cabometyx [EU/DE]

ATC code: L01EX07

Main use (for orientation): Selected cancers

Documented research summary

CBD enhanced cabozantinib-induced apoptosis in HCC cells; not a clinically investigated combination.

Uncertainties and limitations

COMETRIQ capsules, not automatically Cabometyx tablets: formulation-specific pharmacokinetics.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0183

Type of result: Preclinical evidence

Observation: Increased cytotoxicity and apoptosis in the combination; attenuated by p53/ER-stress inhibition, not explained by CNR1/CNR2.

Mechanism: ER stress/p53 phosphorylation

Study type: Cell experiment

Context studied: HCC cell experiments; no patients or pharmacokinetics.

Clinical interpretation: Not a clinical treatment recommendation

Limitations and uncertainties: Abstract reviewed; do not transfer in vitro concentrations and effects to medicine use in humans.

Original sources for this finding: Cannabidiol Enhances Cabozantinib-Induced Apoptotic Cell Death via Phosphorylation of p53 Regulated by ER Stress in Hepatocellular Carcinoma. [BMED37568803]

References and access status

[V2_LABEL_D0382] COMETRIQ (CABOZANTINIB) KIT COMETRIQ (CABOZANTINIB) CAPSULE [EXELIXIS, INC.]

Original source / bibliographic reference

Authors: Exelixis, Inc.

Year: 2025

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED37568803] Cannabidiol Enhances Cabozantinib-Induced Apoptotic Cell Death via Phosphorylation of p53 Regulated by ER Stress in Hepatocellular Carcinoma.

Original source / bibliographic reference

Authors: Jeon Y, Kim T, Kwon H, Kim JK, Park YT, Ham J, Kim YJ.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.3390/cancers15153987

PMID: 37568803

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility